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Abstract
Male breast cancer is an extremely rare malignancy. We treated three male breast cancer patients. All three
patients showed clinical N0 and received sentinel lymph node biopsy. Because the sentinel lymph node was
positive for metastasis in one patient, a total mastectomy with axillary lymph node dissection was performed.
The other two patients were negative for sentinel lymph node metastasis, and a simple mastectomy was performed. Two
of the patients were postoperatively treated with tamoxifen; another patient was treated with adjuvant chemotherapy
using taxotere and cyclophosphamide before tamoxifen. There was no recurrence in any of the three patients during an
average follow-up period of 56.7 months (range 11.8–80.3). A sentinel lymph node biopsy is recommended for node
staging in both male and female breast cancer patients as it is associated with a lower incidence of complications.
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Background
Male breast cancer (MBC) is an extremely rare malig-
nancy which accounts for 1 % of all breast cancers and
0.1 % of all male cancers [1]. In spite of the low inci-
dence of MBC, it is associated with a higher mortality
than female breast cancer (FBC), due to the more ad-
vanced staging of patients at the time diagnosis [2]. In
2013, only 82 of the 13,230 patients in Japan who died
as a result of breast cancer were males [3]. Because of
the rarity of MBC, its etiology is less clear than FBC.
The management of patients with MBC generally de-
pends on the information from the diagnosis and the
processes and treatments of FBC. However, in contrast
to FBC patients who are more often treated with breast-
conserving surgery, most MBC patients are treated with
simple mastectomy with axillary lymph node dissection
(ALND) or sentinel lymph node biopsy (SLNB) [4–6].
We herein report three MBC cases with information on
the diagnostic procedures and management, including
the performance of SLNB.
Case presentation
SLNB: At the day before operation, sentinel lymphoscin-
tigraphy was performed, with the injection of 99 m Tc
(0.2 ml) using a Techne Phytate Kit. Sentinel lymph
nodes (SLNs) were detected with a hand-held gamma
probe (Navigator GPS, Sheen man, Osaka, Japan). When
an excisional biopsy had already been carried out, sub-
dermal injection was performed near the scar. Planar
scintigraphic scans of the involved breast and the axillary
region in the anterior and anterior-oblique projections
were carried out after 4 h of injection.
Under general anesthesia, indocyanine green (1 ml)
was injected into the periareolar skin and periphery of
tumor for SLNB by the dye method. SLNs were traced
by the Navigator GPS and confirmed by the presence of
a radioisotope and dye. The pathological diagnosis of the
resected SLNs was performed during surgery.
Case 1
A 64-year-old man presented to his family doctor com-
plaining of a tumor in his right breast that had been
present for 2 years. A CT showed a round tumor of
10 mm in diameter under the nipple. There was no evi-
dence of axillary lymph node swelling or metastatic dis-
ease (Fig. 1). Mammography (MMG) and ultrasonography
(US) were not performed. An excisional biopsy was
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performed, which revealed an invasive ductal carcin-
oma with a close margin (<5 mm). He was introduced to
our hospital for operation. The clinical diagnosis was
cT1cN0M0, stage I. Because the pathological margin of
the excisional biopsy was close (<5 mm), we explained to
the merits and demerits of the different procedures (in-
cluding partial mastectomy or total mastectomy), and an
operation was selected. In our breast surgery department,
MRI of the breast is usually performed for patients who
intend to undergo partial mastectomy. We therefore per-
formed total mastectomy and SLNB.
On the day before the operation, sentinel lymphoscin-
tigraphy was performed. The SLNs were indicated by
the combination of a radioisotope and blue dye. No me-
tastasis was found in the intraoperative examination of
frozen sections of four SLNs. After the SLNB, a total
mastectomy of the right breast was performed. In the
pathological examination of the SLNs, an H&E staining
showed no metastasis. The tumor was diagnosed as an
invasive ductal carcinoma (histological grade 1, estrogen
receptor (ER)-positive, progesterone receptor (PR)-
positive, HER2 0). The final diagnosis was pT1bN0M0,
stage I. Because of the ER and PgR positivity of the
tumor, the patient was treated with tamoxifen (20 mg)
for 5 years (Table 1). The patient did not suffer any
complications and remains alive without any recurrent
disease at 80.3 months after the surgery.
Case 2
A 64-year-old man visited to our hospital complaining
of a tumor in his left breast that had been present for
at least 3 months. A US scan showed a well-defined round
tumor measuring 16 mm in diameter under the nipple
(Fig. 2a). A cytological analysis of a fine needle aspiration
biopsy specimen suggested malignancy. A CT scan showed
a round tumor of 16 mm in diameter under the nipple
without axillary lymph node swelling or distant metastasis
(Fig. 2b). MMG were not performed. The clinical diagnosis
was cT1cN0M0, stage I. On the day before the operation,
sentinel lymphoscintigraphy was performed. Under general
anesthesia, SLNB was performed by the radioisotope and
dye method. The pathological diagnosis of the resected
SLNs was conducted during surgery. No metastasis was
found in the intraoperative examination of frozen sections
of the two SLNs. After the SLNB, a total mastectomy of
the left breast was performed. The tumor was diagnosed as
an invasive ductal carcinoma (histological grade 1,
ER-positive, PR-positive, HER2 0, Ki67 index 22.3 %).
The pathological examination of the SLNs showed no
signs of metastasis. The final diagnosis was pT1cN0M0,
stage I. Because of the ER and PgR positivity of the tumor,
the patient was treated with tamoxifen (20 mg) for 5 years.
The patient did not suffer any complications and remains
alive without any recurrent disease at 78 months after
surgery.
Case 3
A 69-year-old man presented to his family doctor com-
plaining of a tumor in his right breast that he noticed a
few days before his presentation. A US scan showed a
well-defined round tumor of 25 mm in diameter under
the nipple (Fig. 3a). A core needle biopsy suggested inva-
sive ductal carcinoma. A CT scan showed a tumor of
24 mm in diameter under the nipple without axillary
lymph node swelling or distant metastasis (Fig. 3b). He
was referred to our hospital for surgery. The clinical
diagnosis was cT2N0M0, stage IIA. On the day before
operation, sentinel lymphoscintigraphy was performed.
SLNB was performed by the radioisotope and dye
method. A pathological examination of the three re-
moved SLNs was conducted pathological during surgery,
which showed metastasis in one SLN. After SLNB, a
Fig. 1 A preoperative chest CT scan showing the incisional biopsy
scar (arrow) of the right breast carcinoma
Table 1 The clinical and pathological characteristics of three male breast cancer patients
Case Age Tumor size (mm) T N M Stage Histology Nuclear grade ER PgR HER2 Ki67 Adjuvant therapy
1 64 10 1 0 0 I Solid-tubular carcinoma 1 + + 0 Unknown Tamoxifen 20 mg
2 64 16 1 0 0 I Solid-tubular carcinoma 1 + + 0 Unknown Tamoxifen 20 mg




T tumor, N lymph node, M metastasis
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total mastectomy of the left breast was performed with
level II axillary lymph node dissection. The tumor was
diagnosed as an invasive ductal carcinoma (histological
grade 3, ER-positive, PR-positive HER2 score 0, Ki67
index 21 %). A pathological examination showed metas-
tasis in 2 of 15 axillary lymph nodes. The final diagno-
sis was pT2N1M0, stage IIB. Adjuvant chemotherapy,
consisting of taxotere (75 mg/m2, 120 mg/body), and
cyclophosphamide (600 mg/m2, 1000 mg/body) was
administered in four courses following the standard treat-
ment guidelines for FBC. Adjuvant chemotherapy without
anthracycline was administered because of the patient’s
hypertension. After chemotherapy, he was treated with
tamoxifen (20 mg) due to the ER and PgR positivity of the
tumor. The patient experienced axillary paresthesia, a de-
creased range of motion of the shoulder and arm, but has
experienced no recurrence in the 10 months since surgery.
Discussion
MBC is a rare malignant tumor, which accounts for less
than 1 % of breast cancer cases [1]. The median age at
diagnosis among MBC patients is 67–71 years, slightly
older than the median age of 61 years in female patients
[7, 8]. Because MBC tumors are likely to express ER
and PgR, the use of adjuvant hormonal therapy is bene-
ficial [5]. Some reports have suggested that the fre-
quency of high expression human epidermal growth
factor 2 (HER2) is low [9–11]. In this study, all three
patients showed ER-positive and HER2 scores of 0 and
were treated with tamoxifen. The side effects of tamoxifen
include weight gain, hot flashes, decreased sexual desire
or ability, and mood swings. The side effects occur more
frequently in MBC patients than in FBC patients [12].
Our patients reported no side effects in relation to the
administration of tamoxifen during the follow-up period.
Because of the rarity of MBC, the etiology of MBC is less
clear than the etiology of FBC. The management of pa-
tients with MBC generally depends on the information
from the diagnosis process and the treatments that are ap-
plied to patients with FBC. We are currently continuing
to treat case 3 with tamoxifen (20 mg), while being careful
to identify the occurrence of any adverse events.
Fig. 2 a A preoperative US scan showing a round mass of 16 mm in diameter in the left subareolar area. b A preoperative chest CT scan showing a
round tumor of 16 mm in diameter in the left subareolar area
Fig. 3 a A preoperative US scan showing a round mass of 24 mm in diameter in the right subareolar area. b A preoperative chest CT scan showing a
round tumor of 24 mm in diameter in the right subareolar area
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The prognosis of MBC had been reported to be worse
than that of FBC. The reason for the lower overall sur-
vival associated with MBC is the higher age of suscepti-
bility and the higher rate of cases who are diagnosed
with advanced stage MBC [2]. When adjusted for the ex-
pected survival rate of the US population, race, gender,
and age, no differences were found in the 5-year survival
rate for MBC and FBC. The 5-year survival rate at each
stage of MBC vs. FBC is 96 vs. 99 % (stage I), 84 vs.
84 % (stage II), 52 vs. 55 % (stage III), and 24 vs. 18 %
(stage IV), respectively [8]. Due to the lack of knowledge
about MBC, patients may take longer to seek medical
treatment after noticing, which may result in an increase
in the tumor diameter [13]. Cases of MBC are often di-
agnosed due to the presence of a breast tumor [14].
In this case report, we performed mastectomy for all
three patients. We usually explained the merits and de-
merits of the different procedures (including partial
mastectomy or total mastectomy) to each patient. Al-
though there were no statistically significant differences
in the survival rates of the patients who underwent
total mastectomy and partial mastectomy followed by
irradiation, the local recurrence rate was higher in the
patients who underwent partial mastectomy. To date,
no studies have shown the superiority of the breast-
conserving surgery (BCS) for male patients. As a result,
we select mastectomy with SLNB for our male patients.
A simple mastectomy is the most common surgery for
MBC patients, because it is associated with a lower rate
of local recurrence rate in comparison to BCS [6]. Al-
most all male patients are treated with mastectomy,
due to small volume of breast tissue in comparison to
females. BCS for FBC patients is the standard therapy
because it is associated with a lower level of mental an-
guish. In contrast, male patients show less mental anguish
in association with breast loss. Furthermore, radiotherapy
is necessary for BCS, which involves a long treatment
period and increased medical costs. It is therefore reason-
able to enforce mastectomy in MBC patients. There are
no reports of differences in the incidence of postoperative
complications in MBC and FBC patients. Generally, the
rate of males who engage in manual labor is higher than
that in females; therefore, the influence ALND is higher in
MBC patients than in FBC patients.
ALND may be associated with scarring, axillary
paresthesia, a decreased range of motion of the shoulder
and arm, and lymphedema [15]. Although the usefulness
of SLNB in female patients has been proven [16], it is diffi-
cult to establish the usefulness and safety of SLNB in
MBC patients, but it is important to accumulate data.
The patient who underwent ALND showed axillary
paresthesia, a decreased range of motion of the shoul-
der and arm, while the other two patients who only
underwent SLNB did not show any complications. As
in FBC patients, SLNB is recommended for staging the
axilla in MBC patients and is associated with fewer com-
plications than ALND. Overgaard et al. suggested that the
survival benefit after postmastectomy RT was substantial
and similar in patients with 1–3 and 4+ positive lymph
nodes in a subgroup analysis of randomized trials [17]. In
case 3, we explained the potential survival benefit associ-
ated with radiation therapy after chemotherapy, but the
patient refused to undergo radiation therapy because of
the long-term nature of the treatment.
Conclusions
Although MBC is rare disease, a clinical trial is necessary
to establish a standard treatment for MBC. In this study,
three male patients with breast cancer were treated the
same as female patients, and all patients remain alive
without recurrence.
Consent
We routinely obtained general consent from every pa-
tient for using their clinical data before surgery. Written
informed consent was not obtained from the patient for
publication of this case report because this report is just
a retrospective case report without additional invasive
examinations or treatments for the study.
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